VKH
PETX

Virtu KCG Holdings’s Aratana Therapeutics, Inc. PETX Stock Holding History

Virtu KCG Holdings’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-34,726
Closed -$219K – 3666
2016
Q2 		$219K Buy
34,726
+9,789
+39% +$63K ﹤0.01% 2232
2016
Q1 		$138K Buy
+24,937
New +$93.8K ﹤0.01% 2242

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Virtu KCG Holdings's PETX Position: Q3 2016 in Review

Virtu KCG Holdings sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 34,726 shares — an estimated $219K sold.

Virtu KCG Holdings first reported a position in PETX in Q1 2016 and held it in 2 quarters. The position peaked at $219K in Q2 2016. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

  • Virtu KCG Holdings reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 34,726 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $219K.
  • Virtu KCG Holdings first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Aratana Therapeutics, Inc. position peaked at $219K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Virtu KCG Holdings's 13F filing for Q3 2016, filed 10 Nov 2016.